Literature DB >> 8249836

Late outcome after percutaneous transluminal coronary angioplasty during acute myocardial infarction.

B O'Murchu1, B J Gersh, G S Reeder, K R Bailey, D R Holmes.   

Abstract

Early reperfusion for acute myocardial infarction (AMI) results in improved ventricular function and survival. There is a dearth of data on long-term survival (> 5 years) after percutaneous transluminal coronary angioplasty (PTCA) performed either as a primary procedure or in conjunction with thrombolytic therapy. We studied 160 patients who underwent PTCA during AMI between 1981 and 1987 either with (n = 101) or without (n = 59) streptokinase therapy. Mean time to reperfusion was 4.6 hours, and patency was achieved in 134 patients (84%). Mean discharge ejection fraction was 46 +/- 14%. Coronary artery bypass grafting was performed before dismissal in 34 patients (21%), including 21 of 130 patients (16%) with 1- or 2-vessel disease and 13 of 30 patients (43%) with 3-vessel disease (p < 0.05). Eleven patients (7%) died in the hospital. The 149 hospital survivors were followed for a mean of 69 +/- 21 months (median 72). During follow-up, 22 patients (15%) died, 21 (14%) had reinfarction, 23 (15%) underwent coronary artery bypass grafting, and 21 (14%) underwent repeat PTCA of the infarct-related artery. On univariate analysis, age > or = 62 years, multivessel disease, ejection fraction < or = 40%, previous AMI, and being a nonsmoker at the time of AMI were predictive of late mortality (p < 0.05 each variable). On multivariate analysis, only ejection fraction < or = 40% and prior AMI were predictive of late death. In patients treated with PTCA for AMI, late survival is excellent. Early surgical revascularization of high-risk patients may contribute to these encouraging results.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249836     DOI: 10.1016/0002-9149(93)90876-e

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Experience of primary angioplasty in the United Kingdom.

Authors:  D R Ramsdale; E D Grech
Journal:  Br Heart J       Date:  1995-05

Review 2.  Primary coronary angioplasty in acute myocardial infarction.

Authors:  E D Grech; D R Ramsdale
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

3.  Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients.

Authors:  M Aristides; M Gliksman; N Rajan; P Davey
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

4.  Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis.

Authors:  C J McKenna; M Codd; H A McCann; D D Sugrue
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.